- Breast
- Lung
- Hematologic Oncology
- Gastrointestinal
- Genitourinary
- General Oncology
- Sarcoma
- Skin
- Head & Neck
- Event
Playback speed
10 seconds
Analysis of PFS in CLL: Pts Who Received First-Line Bendamustine-Rituximab Depending on The Elimination Rate of The MRD and IGHV
0 views
March 30, 2020
Comments 0
Login to view comments.
Click here to Login
Hematologic Oncology